Healthcare >> Analyst Interviews >> September 30, 2021
D.C. Drug Price Debate Creates Opportunity for Longer-Term Pharma Investors
Kevin Kedra is a Research Analyst with GAMCO Investors. He joined GAMCO in 2005 as a research analyst covering the health care industry. He now covers animal health, biotech and pharma for GAMCO. He graduated from the University of Pennsylvania where he received a B.S.E. in bioengineering. Profile
Word count: 3,118
TWST: Please introduce your coverage and the subsectors you focus on at Gabelli?
Mr. Kedra: I cover pharmaceuticals, focusing more on